VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at American Heart Association Meeting

VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at
American Heart Association Meeting
Extends VisEn's Leading Fluorescence Molecular Imaging Agent Portfolio to
Enable Expanded Readouts of Key Protease Biomarkers in Research and Drug
Development

ORLANDO, Fla., Nov. 12 /PRNewswire/ -- VisEn Medical Inc., a leader in
fluorescence in vivo imaging from research through medicine, announced today
the commercial launch of its new Cat B 750 FAST(TM) imaging agent for
measuring and monitoring cathepsin B activity associated with disease
progression and therapeutic response in vivo. Cathepsin B expression is well
known as a key biomarker and therapeutic target in a range of diseases,
including atherosclerosis, oncology, and arthritis. The new agent is expected
to have a significant impact in cardiovascular disease research, and is being
launched at the American Heart Association Scientific Sessions 2009 in
Orlando.

Cathepsin B proteases play an important role in disease progression and host
response in several disease areas, and are key biomarkers in assessing and
characterizing disease states. The new Cat B 750 FAST(TM) agent is designed
to complement in vitro and in vivo protease readouts from cell-based assays
and VisEn's existing in vivo agent product lines, providing earlier imaging
time points and narrower specificity profiles of cathepsin B within the
cathepsin family of proteases.

The new Cat B 750 FAST(TM) agent represents an additional protease-sensing
agent developed from VisEn's new FAST ("Fluorescent Activatable Sensor
Technology") in vivo agent platform. FAST agents are based on
high-performance activatable smaller molecules that combine advanced biomarker
specificity with optimized biocompatibility and rapid pharmacokinetics. These
benefits allow for precise measurement and monitoring of key disease
biomarkers in vivo.

VisEn also announced the commercial availability of its ReninSense680 FAST(TM)
agent for localized in vivo measurement of changes in renin-angiotensin system
(RAS) involved in hypertension and some neurological diseases.

"We continue to be very pleased with the rapidly expanding capability and
adoption of our fluorescence agents and FMT imaging systems as a standard in
measuring key biologic pathways and biomarkers in vivo," said Kirtland Poss,
President and CEO of VisEn. "We look forward to working further with our
customers in advancing their research and therapeutic development in these
important disease areas."

VisEn's proprietary fluorescence imaging agents and labels are designed to
provide the industry's broadest and most robust range of biologically-specific
imaging readouts in vivo. VisEn offers over 30 different fluorescence
molecular agents for imaging key disease-associated biologic targets,
processes and pathways. VisEn agent brands include ProSense®,
IntegriSense(TM), AngioSense(TM), OsteoSense®, MMPSense(TM), Cat K FAST(TM),
Annexin-Vivo(TM), and now ReninSense FAST and Cat B FAST. VisEn also offers
specialized lines of in vivo agent labeling platforms, including its
proprietary VivoTag® fluorescence labeling dyes for custom agent development
and its NanoSpark® labeling nanoparticles. They are all designed and
optimized specifically for superior biocompatibility, brightness, stability
and performance in in vivo imaging.

All VisEn agents and labels are designed for in vivo biomarker quantification
using VisEn's Fluorescence Molecular Tomography (FMT(TM)) imaging systems, or
for general use along with other non-quantitative fluorescence in vivo imaging
systems. VisEn agents are also designed to enable complementary in vitro
biomarker readouts in cells and tissues using standard fluorescence microscopy
and cellular-based imaging systems. With a focus on translational research
and results, all of VisEn's technologies are designed to generate
translational data linking pre-clinical research into clinical medicine.

About VisEn Medical Inc.
VisEn's in vivo fluorescence imaging technologies, including its Fluorescence
Agent Portfolio and its Fluorescence Molecular Tomography (FMT(TM)) Imaging
Systems, provide robust fluorescence molecular imaging performance in
identifying, characterizing and quantifying ranges of disease biomarkers and
therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by
leading research institutions and pharmaceutical companies worldwide in
applications including cancer research, inflammation, cardiovascular, skeletal
and pulmonary disease. The Company also works with large pharmaceutical and
clinical partners to design ranges of tailored molecular imaging agents and
applications designed for their specific pre-clinical and clinical research
areas.

Additional information can be found at www.visenmedical.com.

SOURCE VisEn Medical Inc.

Robert Sandler, VP, Marketing, VisEn Medical Inc., +1-647-350-1881 (office),
+1-416-274-8166 (cell), rsandler@visenmedical.com; Peter Steinerman,
Principal, Steinerman Biomedical Comm., +1-516-374-3031 (office),
+1-516-641-8959 (cell), PRSteinerman@aol.com